206 related articles for article (PubMed ID: 35217379)
1. Design and synthesis of new 2-oxoquinoxalinyl-1,2,4-triazoles as antitumor VEGFR-2 inhibitors.
Zengin M; Unsal Tan O; Arafa RK; Balkan A
Bioorg Chem; 2022 Apr; 121():105696. PubMed ID: 35217379
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, in vitro antiproliferative evaluation and in silico studies of new VEGFR-2 inhibitors based on 4-piperazinylquinolin-2(1H)-one scaffold.
Hassan A; Badr M; Abdelhamid D; Hassan HA; Abourehab MAS; Abuo-Rahma GEA
Bioorg Chem; 2022 Mar; 120():105631. PubMed ID: 35091289
[TBL] [Abstract][Full Text] [Related]
5. Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies.
Alsaif NA; Taghour MS; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari A; Albassam H; Dahab MA; Mahdy HA
Bioorg Med Chem; 2021 Sep; 46():116384. PubMed ID: 34479065
[TBL] [Abstract][Full Text] [Related]
6. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
Alsaif NA; Elwan A; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Mahdy HA; Taghour MS
Mol Divers; 2022 Aug; 26(4):1915-1932. PubMed ID: 34460053
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and anticancer activity of novel 2-arylbenzimidazole/2-thiopyrimidines and 2-thioquinazolin-4(3H)-ones conjugates as targeted RAF and VEGFR-2 kinases inhibitors.
Ali IH; Abdel-Mohsen HT; Mounier MM; Abo-Elfadl MT; El Kerdawy AM; Ghannam IAY
Bioorg Chem; 2022 Sep; 126():105883. PubMed ID: 35636123
[TBL] [Abstract][Full Text] [Related]
9. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation.
Eissa IH; El-Helby AA; Mahdy HA; Khalifa MM; Elnagar HA; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; El-Adl K
Bioorg Chem; 2020 Dec; 105():104380. PubMed ID: 33128967
[TBL] [Abstract][Full Text] [Related]
10. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
[TBL] [Abstract][Full Text] [Related]
11. The effect of novel synthetic semicarbazone- and thiosemicarbazone-linked 1,2,3-triazoles on the apoptotic markers, VEGFR-2, and cell cycle of myeloid leukemia.
Othman EM; Fayed EA; Husseiny EM; Abulkhair HS
Bioorg Chem; 2022 Oct; 127():105968. PubMed ID: 35728289
[TBL] [Abstract][Full Text] [Related]
12. Exploration of thiazolidine-2,4-diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations.
Aziz NAAM; George RF; El-Adl K; Mahmoud WR
Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200465. PubMed ID: 36403198
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Sakr H; El-Hddad SSA
Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000068. PubMed ID: 32510731
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Nasser M; Abulkhair HS; El-Hddad SSA
Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000279. PubMed ID: 33073374
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents.
Roaiah HM; Ghannam IAY; Ali IH; El Kerdawy AM; Ali MM; Abbas SE; El-Nakkady SS
Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29323750
[TBL] [Abstract][Full Text] [Related]
16. Novel antiproliferative agents bearing substituted thieno[2,3-d]pyrimidine scaffold as dual VEGFR-2 and BRAF kinases inhibitors and apoptosis inducers; design, synthesis and molecular docking.
Hassan RA; Hamed MIA; Abdou AM; El-Dash Y
Bioorg Chem; 2022 Aug; 125():105861. PubMed ID: 35569190
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of novel hexahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives as potential anticancer agents with antiangiogenic activity via VEGFR-2 inhibition, and down-regulation of PI3K/AKT/mTOR signaling pathway.
Seif SE; Mahmoud Z; Wardakhan WW; Abdou AM; Hassan RA
Drug Dev Res; 2023 Aug; 84(5):839-860. PubMed ID: 37016480
[TBL] [Abstract][Full Text] [Related]
18. Identification of new benzimidazole-triazole hybrids as anticancer agents: multi-target recognition,
Othman DIA; Hamdi A; Tawfik SS; Elgazar AA; Mostafa AS
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2166037. PubMed ID: 36651111
[TBL] [Abstract][Full Text] [Related]
19. Novel 4-(piperazin-1-yl)quinolin-2(1H)-one bearing thiazoles with antiproliferative activity through VEGFR-2-TK inhibition.
Hassan A; Badr M; Hassan HA; Abdelhamid D; Abuo-Rahma GEA
Bioorg Med Chem; 2021 Jun; 40():116168. PubMed ID: 33962153
[TBL] [Abstract][Full Text] [Related]
20. Discovery of New VEGFR-2 Inhibitors: Design, Synthesis, Anti-Proliferative Evaluation, Docking, and MD Simulation Studies.
Elkaeed EB; Yousef RG; Khalifa MM; Ibrahim A; Mehany ABM; Gobaara IMM; Alsfouk BA; Eldehna WM; Metwaly AM; Eissa IH; El-Zahabi MA
Molecules; 2022 Sep; 27(19):. PubMed ID: 36234734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
